Trpti

Oleoylethanolamide (OEA) is an endogenous fatty acid amide (COOH N) that belongs to the ethanolamide family.

It is a biologically active (bioactive) mono-unsaturated lipid mediator.

OEA is derived from oleic acid, an 18-carbon monounsaturated fatty acid (18:1, n-9), and is synthesised in the gastrointestinal tract (intestinal epithelial cells (enterocytes), fat tissues, neurons, and astrocytes.

What is Trpti™

Trpti™ is a novel ingredient that contains a combination of Oleoylethanolamide (OEA) with LipiSperse® dispersion technology.

LipiSperse® is a cold-water dispersion technology designed to promote the solubility and bioavailability of lipophilic compounds such as OEA and contains no bioactive properties itself.

The technology makes use of surfactants, polar lipids, and solvents that embed into OEA’s crystal structure whilst:

  • maintaining surface hydrophilicity
  • increasing water dispersibility and solubility
  • preventing crystal agglomeration and clumping
Glucose metabolism

Enhanced glycaemic control

Promotes glycogen synthesis (glycogenesis) and suppresses liver glucose production (gluconeogenesis) by activating liver kinase B1 (LKB1) and 5’ AMP-activated protein kinase (AMPK) signaling pathways in the liver

Lower blood glucose levels

Reduced postprandial glucose levels

Insulin, Lipids, and Liver enzymes

Lower insulin levels

Lower HOMA-IR (Homeostatic Model Assessment of Insulin Resistance)

Promotes fatty acid oxidation

Improved triglyceride metabolism

Increased HDL-C

Reduced ALT and AST liver enzyme concentrations

Anti-inflammatory effects

Reduced:
Interleukin-6 (IL-6)
Tumour necrosis factor-alpha (TNF-α)
C-Reactive Protein (CRP)
Expression and signalling of nuclear factor-kappa B (NF-κB)

Activates:
Peroxisome proliferator-activated receptor alpha (PPAR-α)

Antioxidant effects

Increased total antioxidant capacity (TAC)

Increased superoxide dismutase (SOD)

Reduced malondialdehyde (MDA)

Reduced oxidised LDL (ox-LDL)

Suppresses general ROS

Digestive, Satiety

Delayed meal initiation

Appetite regulation and suppressed appetite

Enhanced satiety

Energy and carbohydrate intakes decreased

Decreased cravings for sweet foods

Decreased gastric emptying

Anthropometric

Reduced body weight.

Reduced BMI

Reduced waist circumference

Reduced body fat percentage

Reduced fat mass

Increased feelings of fullness

Randomised, double-blind, placebo-controlled trial

300 mg of TRPTI™ (providing 250 mg/day of OEA) or Placebo for 12 weeks.

OEA was safe and well-tolerated with no adverse changes in clinical biomarkers.

Results

Increased:

  • Akkermansia muciniphila
  • Faecalibacterium prausnitzii

Additionally:

  • Enhanced microbial metabolic and redox capacity
  • Improved epithelial barrier dynamics (increased occludin)
  • Reduced inflammation

Notes

Adults only. Not recommended for children, pregnant, or breastfeeding individuals.

For information purposes only. Not a substitute for medical advice. If symptoms persist, talk to a health professional. Always read the label. Follow the directions for use.